The Israeli company has developed a microbiome human discovery platform that offers a glycemic control solution for people with type II diabetes.
Israeli personalized nutrition company DayTwo has expanded its $31 million Series B financing round with an additional $5 million investment from Longliv Ventures and unspecified amounts from Cathay Innovation and Samsung NEXT. Longliv Ventures managing director Dr. Dan Eldar will join the company’s board.